Trials / Completed
CompletedNCT05244668
Multicenter Validation of the Salivary miRNA Signature of Endometriosis
Multicenter Validation of the Salivary miRNA Signature of Endometriosis - The ENDOmiARN Salive Test Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,140 (actual)
- Sponsor
- ZIWIG · Industry
- Sex
- Female
- Age
- 18 Years – 43 Years
- Healthy volunteers
- —
Summary
ENDOmiARN Salive Test is a multicentre external validation study of a salivary signature of endometriosis carried out in France in Obstetrics and Reproductive Medicine departments, in order to evaluate its performance and discuss its use in clinical practice. The clinical application is to significantly reduce the time to diagnosis and improve the care pathway for endometriosis. The study population is made up of women aged 18 to 43 years with formally diagnosed endometriosis or suspected endometriosis who are already receiving either medical (MAP) or surgical treatment as part of their routine care. The patients concerned by the study are managed without any change in the care pathway, nor any change in the therapeutic indications, nor any change in the diagnostic examinations (imaging or biology) required according to the context, which are carried out in accordance with the HAS recommendations. In this study, the management and follow-up of patients : * Are not imposed by the study: the doctor remains free to make medical prescriptions (treatments and examinations) and to determine the interval between consultation visits, * Are not modified in comparison with the usual follow-up, except for the performance of : * Collection of saliva * Electronic collection of the answers to the questionnaires completed by the patient
Conditions
Timeline
- Start date
- 2021-12-15
- Primary completion
- 2023-01-06
- Completion
- 2026-02-28
- First posted
- 2022-02-17
- Last updated
- 2026-03-27
Locations
18 sites across 2 countries: Canada, France
Source: ClinicalTrials.gov record NCT05244668. Inclusion in this directory is not an endorsement.